GAL-101: Novel small molecule delivered as eye drops, entering Phase 2 efficacy trials, designed to offer neuroprotection and improved cellular and visual function for retinal diseases to slow progression toward blindness in patients with dry AMD and glaucoma.

GAL-201: Next generation molecule derived from GAL-101 with improved pharmacology and pharmacokinetics. Now in preclinical development for oral administration, designed to deliver to the brain, eyes, and elsewhere for neuroprotection and improved neural function in retinal diseases and Alzheimer's disease, among others.


Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells (RGCs) and their axons and results in structural and functional damage to the optic nerve, visual disability, and eventual blindness. It affects around 2 percent of the population, increasing with age to 8 percent at the age of 80. Although medical, laser, and incisional surgical treatments are available to lower intraocular pressure, many patients continue to progress and glaucoma remains the world's second leading cause of irreversible blindness. Increasing life expectancy globally increases the number of individuals with the disease and the duration of time they have it, which in turn results in more glaucoma-related disability and personal and societal burden. Given these issues, there is a clear unmet need for a new treatment to improve effectiveness in slowing or halting progression, whether as a supplement to IOP management, or on its own.

Age-related Macular Degeneration

Age related macular degeneration (AMD) is a neuro-degenerative disease that affects about 1 in 4 adults over the age of 65, and 1 in 3 over the age of 75. It is estimated that there are currently around 200 million patients suffering from AMD globally. It is the leading cause of adult blindness in the US and industrialized countries. Most people with AMD have the "dry" form of the condition, in which retinal cells in the central area - the macula - slowly degenerate and die. The result is progressive difficulty with vision. There is currently no approved treatment for slowing down this progressive degeneration and ensuing vision loss. Any drug that targets a central cause of neural cell malfunction and degeneration may alleviate this unmet need and potentially help millions around the world. This is becoming increasingly important as the population ages, with a potential epidemic of AMD.